Added to YB: 2025-03-06
Pitch date: 2025-01-16
KROS [bullish]
Keros Therapeutics, Inc.
+95.6%
current return
Author Info
No bio for this author
Company Info
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.
Market Cap
$525.8M
Pitch Price
$11.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.82
P/E
10.96
EV/Sales
-0.61
Sector
Biotechnology
Category
value
Keros Therapeutics, Inc. - $KROS
KROS: Trading below $15/share net cash after failed Cibotercept trial. $200M from Takeda for KER-050 license. KER-065 neuromuscular drug no longer pursuing weight loss. Risks: Takeda deal confirmation, potential new R&D projects, delay in sale/liquidation. Catalysts: activist involvement, layoffs, corporate action.
Read full article (3 min)